Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
XBIvsARKGETF Comparison
SPDR S&P Biotech ETF (XBI) belongs to the US Health Care segment. ARK Genomic Revolution ETF (ARKG) is part of the BioTech & Genomics segment. Both ETFs have the same top 3 sector exposures: and Health Care. XBI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.75% for ARKG. XBI is up 3.65% year-to-date (YTD) with -$59M in YTD flows. ARKG performs worse with -4.22% YTD performance, and -$14M in YTD flows. Run a side-by-side ETF comparison of XBI and ARKG below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
XBI vs ARKG performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI ARKG | +1.38%-3.97% | +3.11%-10.24% | +3.65%-4.22% | +47.21%+27.40% | +63.16%+1.75% | -13.71%-68.08% |
| Flows | XBI ARKG | -$4M-$69M | -$179M-$81M | -$59M-$14M | +$90M-$206M | -$1.64B-$635M | +$1.20B-$2.75B |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI ARKG | +25.68%+39.15% | +28.04%+44.66% | +27.26%+42.31% | +32.91%+45.26% |
| Max drawdown | XBI ARKG | -8.19%-19.50% | -21.44%-23.94% | -32.94%-51.98% | -57.63%-80.33% |
| Max drawdown duration | XBI ARKG | 48d47d | 141d77d | 331d965d | 1822d1821d |
XBI | ARKG | |
Last sale 3/12/2026 at 1:30 PM | $122.64 | $26.17 |
| Previous close 03/11/2026 | $126.38 | $27.67 |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
XBI | ARKG | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
XBI | ARKG | |
|---|---|---|
| Last price | $122.64 | $26.17 |
| 1D performance | -2.96% | -5.42% |
| AuM | $8.10 B | $1.11 B |
| E/R | 0.35% | 0.75% |
XBI | ARKG | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | SPDR | Ark Investment |
| Benchmark | S&P Biotechnology Select Industry Index | - |
| N° of holdings | 123 | 30 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | April 2, 2019 |
| ESG | No | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the XBI and ARKG ETFs performed in 2026?
As of March 11, 2026, XBI is up 3.65% year-to-date (YTD), while ARKG has lost -4.22%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or ARKG?
Year-to-date, the XBI ETF saw -$59M in flows, compared to -$14M for ARKG.
Which ETF is more volatile: XBI or ARKG?
Over the past year, XBI had a volatility of 28.04%, while ARKG experienced 44.66%.
Which ETF is bigger: XBI or ARKG?
As of March 11, 2026, XBI holds $8.10 B in assets under management (AUM), while ARKG manages $1.11 B.
What sectors do the XBI and ARKG ETFs invest in?
XBI leans toward sectors like Health Care. Meanwhile, ARKG focuses on Health Care.
What are the top holdings of the XBI ETF and ARKG ETF?
XBI top holdings include MODERNA INC, MIRUM PHARMACEUTICALS INC and REVOLUTION MEDICINES INC. ARKG holds in its top three: CRISPR THERAPEUTICS, PERSONALIS INC and GUARDANT HEALTH INC.
Which ETF is more diversified: XBI or ARKG?
XBI holds 149 securities with 21.6% of its assets in the top 15. ARKG has 30 securities and a top 15 weight of 63.79%.
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
Are Biotechnology ETFs In the Midst of a Comeback?
Two biotech ETFs to watch for the rest of 2022 and beyond
Biotech ETFs – Investing in Health Innovation
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
